Back to Search
Start Over
Multicenter evaluation of rapid antimicrobial susceptibility testing by VITEKĀ®2 directly from positive blood culture.
- Source :
-
Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2023 Jul; Vol. 106 (3), pp. 115950. Date of Electronic Publication: 2023 Apr 05. - Publication Year :
- 2023
-
Abstract
- Study Objective: To compare the antimicrobial susceptibility testing (AST) performance of positive blood cultures (PBC) VITEK®2 off-label use (D0) and traditional VITEK®2 workflow using isolated colonies after overnight (D1).<br />Methods: Patient samples with monomicrobial Gram-negative rod or Gram-positive cocci in clusters bacteremia were tested on D0 and compared to D1 AST results in 7 laboratories in France.<br />Results: Overall, categorical and essential agreement rates were 98.4% and 96.7%, respectively. Very major discrepancy and major discrepancy rates for Enterobacterales and Staphylococci satisfied the NF EN ISO 20776-2 (2007) criteria for sepsis-relevant drugs. Very major discrepancies were >3% for amoxicillin-clavulanate (4.9%, 6/122), piperacillin-tazobactam (7.5%, 4/53) and meropenem (33%,1/3) for Enterobacterales and gentamicin for Staphylococci (4.6%, 4/87).<br />Conclusion: Direct AST from PBC broths by VITEK®2 for Enterobacterales and Staphylococci is reliable and fast and may positively influence antimicrobial stewardship.<br /> (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1879-0070
- Volume :
- 106
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Diagnostic microbiology and infectious disease
- Publication Type :
- Academic Journal
- Accession number :
- 37182374
- Full Text :
- https://doi.org/10.1016/j.diagmicrobio.2023.115950